Vitamin D as an anti-microbial and anti-inflammatory therapy for Cystic Fibrosis

Paediatric Respiratory Reviews

Volumn 15, Issue 2, 2014, Pages 154-162

  Herscovitch, K ^a   Dauletbaev, N ^a   Lands, Larry C ^a,b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Anti inflammatory; Anti microbial; Cystic fibrosis; Treatment; Vitamin D

Indexed keywords

CALCITRIOL; COLECALCIFEROL; CORTICOSTEROID; ERGOCALCIFEROL; PARICALCITOL; VITAMIN D;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; BONE ATROPHY; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; DOSE CALCULATION; DOSE RESPONSE; DRUG CHOICE; DRUG MECHANISM; HUMAN; HYPERCALCEMIA; IMMUNOMODULATION; LUNG FUNCTION; NONHUMAN; NUTRITIONAL STATUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; BACTERIAL INFECTIONS; CHILD; COMPLICATION; INFLAMMATION; MICROBIOLOGY;

BACTERIAL INFECTIONS; CHILD; CYSTIC FIBROSIS; HUMANS; INFLAMMATION; VITAMIN D;

EID: 84893982168     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2013.11.002     Document Type: Review

References (105)

1. Cohen-Cymberknoh M., Shoseyov D., Kerem E. Managing Cystic Fibrosis. Am J Respir Crit Care Med 2011, 183:1463-1471.
2. Stenbit A.E., Flume P.A. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2011, 17:442-447.
3. Tirouvanziam R., de Bentzmann S., Hubeau C., et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir.Cell Mol Biol 2000, 23:121-127.
4. Cohen T.S., Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012, 18:509-519.
5. Pillarisetti N., Williamson E., Linnane B., et al. Infection, Inflammation, and Lung Function Decline in Infants with Cystic Fibrosis. Am J Respir Crit Care Med 2011, 184:75-81.
6. Zlosnik J.E.A., Costa P.S., Brant R., et al. Mucoid and Nonmucoid Burkholderia cepacia Complex Bacteria in Cystic Fibrosis Infections. Am J Respir Crit Care Med 2011, 183:67-72.
7. Muhlebach M., Stewart P., Leigh M., Noah T.L. Quantitation of Inflammatory Responses to Bacteria in Young Cystic Fibrosis and Control Patients. Am J Respir.Crit Care Med 1999, 160:186-191.
8. Muhlebach M., Noah T.L. Endotoxin Activity and Inflammatory Markers in the Airways of Young Patients with Cystic Fibrosis. Am J Respir Crit Care Med 2002, 165:911-915.
9. Konstan M.W., Morgan W.J., Butler S.M., et al. Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis. J Pediatr 2007, 151:134-139.
10. Konstan M.W., Wagener J.S., VanDevanter D.R., et al. Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. J Cyst Fibros 2012, 11:405-411.
11. Sagel S.D., Wagner B.D., Anthony M.M., Emmett P., Zemanick E.T. Sputum Biomarkers of Inflammation and Lung Function Decline in Children with Cystic Fibrosis. Am J Respir Crit Care Med 2012, 186:857-865.
12. Taylor-Robinson D., Whitehead M., Diderichsen F., et al. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax 2012, 67:860-866.
13. Lands L.C., Milner R., Cantin A.M., Manson D., Corey M. High-Dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. J Pediatr 2007, 151:249-254.
14. Cheng K., Ashby D., Smyth R.L. Oral steroids for long-term use in cystic fibrosis. Cochrane Database Syst Rev 2011, CD000407-.
15. Flume P.A., O'Sullivan B.P., Robinson K.A., et al. Cystic Fibrosis Pulmonary Guidelines. Am J Respir Crit Care Med 2007, 176:957-969.
16. Wang T.T., Nestel F.P., Bourdeau V., et al. Cutting Edge: 1,25-Dihydroxyvitamin D3 Is a Direct Inducer of Antimicrobial Peptide Gene Expression. J Immunol 2004, 173:2909-2912.
17. Zhang Y., Leung D.Y., Richers B.N., Vitamin D., et al. inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012, 188:2127-2135.
18. Grey V., Atkinson S., Drury D., et al. Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics 2008, 122:1014-1020.
19. Grey V., Lands L., Pall H., Drury D. Monitoring of 25-OH vitamin D levels in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2000, 30:314-319.
20. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
21. Speeckaert M.M., Wehlou C., Vandewalle S., Taes Y.E., Robberecht E., Delanghe J.R. Vitamin D binding protein, a new nutritional marker in cystic fibrosis patients. Clin Chem Lab Med 2008, 46:365-370.
22. Hansdottir S., Monick M.M., Hinde S.L., Lovan N., Look D.C., Hunninghake G.W. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 2008, 181:7090-7099.
23. Baeke F., Takiishi T., Korf H., Gysemans C., Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010, 10:482-496.
24. Aris R.M., Ontjes D.A., Buell H.E., et al. Abnormal bone turnover in cystic fibrosis adults. Osteoporos Int 2002, 13:151-157.
25. Heaney R.P. Vitamin D in Health and Disease. Clin J Am Soc Nephrol 2008, 3:1535-1541.
26. Norman A.W., Okamura W.H., Bishop J.E., Henry H.L. Update on biological actions of 1alpha, 25(OH)2-vitamin D3 (rapid effects) and 24R,25(OH)2-vitamin D3. Mol Cell Endocrinol 2002, 197:1-13.
27. Neville L.A., Ranganathan S.C. Vitamin D in infants with cystic fibrosis diagnosed by newborn screening. J Paediatr Child Health 2009, 45:36-41.
28. Rovner A.J., Stallings V.A., Schall J.I., Leonard M.B., Zemel B.S. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr 2007, 86:1694-1699.
29. Sokol R.J., Reardon M.C., Accurso F.J., et al. Fat-soluble vitamins in infants identified by cystic fibrosis newborn screening. Pediatr Pulmonol Suppl 1991, 7:52-55.
30. Boyle M.P., Noschese M.L., Watts S.L., Davis M.E., Stenner S.E., Lechtzin N. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med 2005, 172:212-217.
31. Donovan D.S., Papadopoulos A., Staron R.B., et al. Bone Mass and Vitamin D Deficiency in Adults with Advanced Cystic Fibrosis Lung Disease. Am J Respir Crit Care Med 1998, 157:1892-1899.
32. Elkin S.L., Fairney A., Burnett S., et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int 2001, 12:366-372.
33. Stephenson A., Brotherwood M., Robert R., Atenafu E., Corey M., Tullis E. Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr 2007, 85:1307-1311.
34. Hanley D.A., Cranney A., Jones G., et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010, 182:E610-E618.
35. Tangpricha V., Kelly A., Stephenson A., et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012, 97:1082-1093.
36. Mailhot G. Vitamin D bioavailability in cystic fibrosis: a cause for concern?. Nutr Rev 2012, 70:280-293.
37. Kopp B.T., Hayes D., Ratkiewicz M., Baron N., Splaingard M. Light exposure and depression in hospitalized adult patients with cystic fibrosis. J Affect Disord 2013.
38. Burdge D.R., Nakielna E.M., Rabin H.R. Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1995, 39. 793.
39. Almajed A., Lands L.C. The evolution of exercise capacity and its limiting factors in Cystic Fibrosis. Paediatr Respir Rev 2012, 13:195-199.
40. Cystic Fibrosis Foundation Patient Registry 2011 Annual Data Report. 2012;.
41. Bronstein M.N., Sokol R.J., Abman S.H., et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992, 120:533-540.
42. Khazai N.B., Judd S.E., Jeng L., et al. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. J Clin Endocrinol Metab 2009, 94:2037-2043.
43. Brodlie M., Orchard W.A., Reeks G.A., et al. Vitamin D in children with cystic fibrosis. Arch Dis Child 2012, 97:982-984.
44. Shepherd D., Belessis Y., Katz T., Morton J., Field P., Jaffe A. Single high-dose oral vitamin D(3) (stoss) therapy - A solution to vitamin D deficiency in children with cystic fibrosis?. J Cyst Fibros 2012.
45. Shea M.K., Benjamin E.J., Dupuis J., et al. Genetic and non-genetic correlates of vitamins K and D. Eur J Clin Nutr 2009, 63:458-464.
46. Wang T.J., Zhang F., Richards J.B., et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010, 376:180-188.
47. Janssens W., Bouillon R., Claes B., et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010, 65:215-220.
48. Adams J.S., Sharma O.P., Gacad M.A., Singer F.R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 1983, 72:1856-1860.
49. Herscovitch K., Dauletbaev N., Berube J., Rousseau S., Lands L. Supplementation With 25-Hydroxyvitamin D3 Down-Regulates Pathogen-Stimulated Interleukin-8 Production In Cystic Fibrosis Macrophages And Airway Epithelial Cells. Am J Respir Crit Care Med 2012, 185. A2803-.
50. Skversky A.L., Kumar J., Abramowitz M.K., Kaskel F.J., Melamed M.L. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006. J Clin Endocrinol Metab 2011, 96:3838-3845.
51. Searing D.A., Zhang Y., Murphy J.R., Hauk P.J., Goleva E., Leung D.Y. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol 2010, 125:995-1000.
52. Kurahashi I., Matsunuma A., Kawane T., Abe M., Horiuchi N. Dexamethasone enhances vitamin D-24-hydroxylase expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treated with 1alpha, 25-dihydroxyvitamin D3. Endocrine 2002, 17:109-118.
53. Abreu M.T., Kantorovich V., Vasiliauskas E.A., et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 2004, 53:1129-1136.
54. Hollox E.J., Armour J.A.L., Barber J.C.K. Extensive Normal Copy Number Variation of a Beta-Defensin Antimicrobial-Gene Cluster. The American Journal of Human Genetics 2003, 73:591-600.
55. Yim S., Dhawan P., Ragunath C., Christakos S., Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3). J Cyst.Fibros 2007, 6:403-410.
56. Liu M.C., Xiao H.Q., Brown A.J., Ritter C.S., Schroeder J. Association of vitamin D and antimicrobial peptide production during late-phase allergic responses in the lung. Clin Exp Allergy 2012, 42:383-391.
57. Adams J.S., Ren S., Liu P.T., et al. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol 2009, 182:4289-4295.
58. MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997, 15:323-350.
59. Rockett K.A., Brookes R., Udalova I., Vidal V., Hill A.V., Kwiatkowski D. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun 1998, 66:5314-5321.
60. Chalmers J.D., McHugh B.J., Docherty C., Govan J.R., Hill A.T. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013, 68:39-47.
61. Ginde A.A., Mansbach J.M., Camargo C.A. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009, 169:384-390.
62. Roth D.E., Shah R., Black R.E., Baqui A.H. Vitamin D status and acute lower respiratory infection in early childhood in Sylhet, Bangladesh. Acta Paediatr. 2010, 99:389-393.
63. Lowery E.M., Bemiss B., Cascino T., et al. Low vitamin D levels are associated with increased rejection and infections after lung transplantation. J Heart Lung Transplant 2012, 31:700-707.
64. McNally P., Coughlan C., Bergsson G., et al. Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis. J Cyst Fibros 2011, 10:428-434.
65. Majak P., Jerzynska J., Smejda K., Stelmach I., Timler D., Stelmach W. Correlation of vitamin D with Foxp3 induction and steroid-sparing effect of immunotherapy in asthmatic children. Ann Allergy Asthma Immunol 2012, 109:329-335.
66. Sutherland E.R., Goleva E., Jackson L.P., Stevens A.D., Leung D.Y. Vitamin D levels, lung function, and steroid response in adult asthma. Am J Respir Crit Care Med 2010, 181:699-704.
67. Chen Y., Liu W., Sun T., et al. 1,25-Dihydroxyvitamin D Promotes Negative Feedback Regulation of TLR Signaling via Targeting MicroRNA-155-SOCS1 in Macrophages. J Immunol 2013, 190:3687-3695.
68. Sadeghi K., Wessner B., Laggner U., et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006, 36:361-370.
69. Hansdottir S., Monick M.M., Lovan N., Powers L., Gerke A., Hunninghake G.W. Vitamin D Decreases Respiratory Syncytial Virus Induction of NF-kappaB-linked Chemokines and Cytokines in Airway Epithelium While Maintaining the Antiviral State. J Immunol 2010, 184:965-974.
70. Riis J.L., Johansen C., Gesser B., et al. 1alpha, 25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. Arch Dermatol Res 2004, 296:195-202.
71. Stio M., Martinesi M., Bruni S., et al. The Vitamin D analogue TX 527 blocks NF-kappaB activation in peripheral blood mononuclear cells of patients with Crohn's disease. J Steroid Biochem Mol Biol 2007, 103:51-60.
72. Banerjee A., Damera G., Bhandare R., et al. Vitamin D and glucocorticoids differentially modulate chemokine expression in human airway smooth muscle cells. Br J Pharmacol 2008, 155:84-92.
73. Xystrakis E., Kusumakar S., Boswell S., et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006, 116:146-155.
74. Takano Y., Mitsuhashi H., Ueno K. 1alpha, 25-Dihydroxyvitamin D(3) inhibits neutrophil recruitment in hamster model of acute lung injury. Steroids 2011, 76:1305-1309.
75. Pincikova T., Nilsson K., Moen I.E., et al. Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. Eur J Clin Nutr 2011, 65:102-109.
76. Black P.N., Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest 2005, 128:3792-3798.
77. Persson L.J., Aanerud M., Hiemstra P.S., Hardie J.A., Bakke P.S., Eagan T.M. Chronic obstructive pulmonary disease is associated with low levels of vitamin D. PLoS One 2012, 7. e38934.
78. Alyasin S., Momen T., Kashef S., Alipour A., Amin R. The relationship between serum 25 hydroxy vitamin d levels and asthma in children. Allergy Asthma Immunol Res 2011, 3:251-255.
79. Wu A.C., Tantisira K., Li L., Fuhlbrigge A.L., Weiss S.T., Litonjua A. Effect of vitamin D and inhaled corticosteroid treatment on lung function in children. Am J Respir Crit Care Med 2012, 186:508-513.
80. Jackson T.C., Krauss M.J., Debaun M.R., Strunk R.C., Arbelaez A.M. Vitamin D deficiency and comorbidities in children with sickle cell anemia. Pediatr Hematol Oncol 2012, 29:261-266.
81. Wolfenden L.L., Judd S.E., Shah R., Sanyal R., Ziegler T.R., Tangpricha V. Vitamin D and bone health in adults with cystic fibrosis. Clin Endocrinol (Oxf) 2008, 69:374-381.
82. Chavasse R.J., Francis J., Balfour-Lynn I., Rosenthal M., Bush A. Serum vitamin D levels in children with cystic fibrosis. Pediatr Pulmonol 2004, 38:119-122.
83. Ferguson J.H., Chang A.B. Vitamin D supplementation for cystic fibrosis. Cochrane Database Syst Rev 2012, 4. cd007298.
84. Grossmann R.E., Zughaier S.M., Kumari M., et al. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. Dermatoendocrinol 2012, 4:191-197.
85. Grossmann R.E., Zughaier S.M., Liu S., Lyles R.H., Tangpricha V. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. Eur J Clin.Nutr 2012, 66:1072-1074.
86. Wejse C., Gomes V.F., Rabna P., et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009, 179:843-850.
87. Manaseki-Holland S., Maroof Z., Bruce J., et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet 2012, 379:1419-1427.
88. Lehouck A., Mathieu C., Carremans C., et al. High Doses of Vitamin D to Reduce Exacerbations in Chronic Obstructive Pulmonary DiseaseA Randomized Trial. Ann Intern Med 2012, 156:105-114.
89. Coussens A.K., Wilkinson R.J., Hanifa Y., et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA 2012, 109:15449-15454.
90. Bergman P., Norlin A.C., Hansen S., et al. Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. BMJ Open 2012, 2.
91. Nordin B.C., Need A.G. The relation between serum calcidiol and calcitriol. IBMS BoneKEy 2005, 2:7-16.
92. Hewison M., Zehnder D., Chakraverty R., Adams J.S. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol 2004, 215:31-38.
93. Armas L.A., Hollis B.W., Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004, 89:5387-5391.
94. Tripkovic L., Lambert H., Hart K., et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr 2012, 95:1357-1364.
95. Lagunova Z., Porojnicu A.C., Lindberg F., Hexeberg S., Moan J. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res 2009, 29:3713-3720.
96. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008, 88:582S-586S.
97. Newby M.J., Keim N.L., Brown D.L. Body composition of adult cystic fibrosis patients and control subjects as determined by densitometry, bioelectrical impedance, total-body electrical conductivity, skinfold measurements, and deuterium oxide dilution. Am J Clin Nutr 1990, 52:209-213.
98. Bischoff-Ferrari H.A., Dawson-Hughes B., Stocklin E., et al. Oral supplementation with 25(OH)D(3) versus vitamin D(3): Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J Bone Miner Res 2012, 27:160-169.
99. Cashman K.D., Seamans K.M., Lucey A.J., et al. Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. Am J Clin Nutr 2012, 95:1350-1356.
100. Peppone L.J., Hebl S., Purnell J.Q., et al. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporos Int 2010, 21:1133-1149.
101. Sambrook P., Henderson N.K., Keogh A., et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000, 15:1818-1824.
102. Tsukamoto Y., Watanabe T., Nakagami T., Morishita K. Effect of treatment with oral calcitriol on calcium metabolism and fasting serum 25(OH)- or 1,25(OH)2-vitamin D level in Japanese postmenopausal women. Endocr J 2003, 50:681-687.
103. Sprague S.M., Llach F., Amdahl M., Taccetta C., Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003, 63:1483-1490.
104. Penna G., Fibbi B., Amuchastegui S., et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009, 69:480-493.
105. Bailie G.R., Johnson C.A. Comparative review of the pharmacokinetics of vitamin D analogues. Semin Dial 2002, 15:352-357.